TipHub

BSE · 524590

Hemo Organic Limited

GSM · GSM 3 Promoter stake −14.34pp
₹20.99
₹7 Cr market cap
P/E
—
EPS
₹0
Book value
₹-0.43
ROE
-22.46%
ROCE
-9.06%
Debt / equity
0

Revenue & net profit by period

Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.

00.621.241.862.48Mar 19Mar 20Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26
Revenue (₹ Cr) Net profit (₹ Cr)

Latest period: revenue ₹1 Cr with net profit ₹-1 Cr — a -83.58% net margin, versus 6.6% the period before.

Shareholding

As of 2026-09-30

2.5%
promoter holding
  • Promoter2.5%
  • Public97.5%

4,728 shareholders on record

Promoter holding trend

Each disclosed period, oldest to newest

16.85%2.5%Dec 24Sep 26

52-week position

Where the current price sits in its yearly band

₹9.71₹20.99₹24.42

The band spans 2.51× from low to high.

Risk flags

Derived from disclosed data

  • Under exchange surveillance — GSM · GSM 3. Trading may carry price bands, periodic call auction or higher margins.
  • Promoter holding fell 14.34 percentage points to 2.5% in the latest disclosure.

Peer comparison

Trading · ranked #519 of 693 by market cap · medians across 50 industry peers

P/E
—vs 34.35 peer med
P/B
0vs 5.09 peer med
ROE %
-22.46vs 13.11 peer med
Margin %
-30.93vs 4.35 peer med
CompanyMkt capP/EP/BROEMargin
Adani Enterprises Limited₹3,63,802 Cr101.433.713.66%4.59%
Avenue Supermarts Limited₹2,24,349 Cr71.988.611.94%4.2%
Trent Ltd.₹1,68,779 Cr88.1221.6924.4%8.62%
FSN E-Commerce Ventures Ltd.₹1,04,618 Cr314.8363.1619.49%2.85%
Aditya Infotech Limited₹50,886 Cr82.3713.8716.16%10.38%
Vishal Mega Mart Limited₹45,148 Cr50.195.711.37%6.45%
Aegis Logistics Limited₹42,976 Cr32.266.4520.01%14.99%
Premier Energies Limited₹40,670 Cr22.987.8834.23%19.11%
Redington Limited₹27,339 Cr13.622.5418.62%1.31%
Honasa Consumer Limited₹16,378 Cr57.1711.0219.03%10.3%
Hemo Organic Limited(this company)₹7 Cr—0-22.46%-30.93%

AI analysis

AI-generated · google/gemini-2.5-flash

Hemo Organic Limited is listed with a market capitalization of Rs 8 Cr. As of March 2025, the company reported an EPS of 0.47 and a negative Return on Equity (ROE) of -585.48%. The book value per share is -2.7.

Positives

  • +The company has a debt-to-equity ratio of 0, indicating no outstanding debt.
  • +Promoter pledge is 0%, indicating no shares are pledged by the promoters.
  • +Revenue increased significantly from Rs 0.0226 Cr in Mar 2024 to Rs 2.4842 Cr in Mar 2025.

Negatives

  • −The company reported a negative Net Profit Margin of -82.8%.
  • −Return on Equity (ROE) is significantly negative at -585.48%.
  • −Return on Capital Employed (ROCE) is negative at -17.3412%.
  • −The company has a negative book value of -2.7.
  • −Quarterly results have shown losses in recent periods, with a net profit of -0.07 Cr in June 2026.
  • −The company is under GSM 4 surveillance.

Financial Performance

Hemo Organic Limited reported revenue of Rs 2.4842 Cr in March 2025, a significant increase from Rs 0.0226 Cr in March 2024. The net profit was Rs 0.1639 Cr in March 2025, compared to a net loss of Rs -0.2641 Cr in March 2024. The EPS improved from -0.76 in March 2024 to 0.47 in March 2025.

Profitability & Returns

The company's profitability has been volatile. In March 2025, the Net Profit Margin stood at -82.8%. The Return on Equity (ROE) was -585.48% and Return on Capital Employed (ROCE) was -17.3412% in March 2025, indicating persistent challenges in generating returns from equity and capital.

Balance Sheet

Hemo Organic Limited has a negative book value of -2.7. The debt-to-equity ratio is 0, indicating the absence of debt on its books as of the latest available data. There is no dividend yield reported for the company.

Ownership & Pledges

As of June 30, 2026, promoters held 16.8481% of the company's shares. Public shareholding was 83.1519%. There were no shares pledged by the promoters. The number of shareholders increased from 1390 in September 2016 to 4821 in June 2026.

Regulatory & Surveillance

Hemo Organic Limited is under surveillance with a 'GSM' label and specifically subject to 'GSM 4' measures. This indicates heightened scrutiny from regulators regarding the company's financials or operations.

Data as of — price: 2026-11-14 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.

How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.

Back to Hemo Organic Limitedshare price & fundamentals